Limb-Girdle Muscular Dystrophy Clinical Trial
Official title:
Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy
| Verified date | January 2018 |
| Source | Nationwide Children's Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The objective of this study is to identify and maintain a registry of well-characterized limb-girdle muscular dystrophy (LGMD) patients. Patients seen as part of this study may be candidates for future treatment trials based on their defined genetic classification of LGMD. In the course of this study, the investigators will perform a muscle biopsy and DNA testing in an unlimited number of patients with clinically diagnosed LGMD. The genetic testing will be extended to the family of the study subject in order to better understand true genetic defect.
| Status | Completed |
| Enrollment | 277 |
| Est. completion date | January 1, 2018 |
| Est. primary completion date | January 1, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - any subject with clinical diagnosis of LGMD - must visit Columbus Children's Hospital for 2-day study visit - muscle biopsy tissue must be available; either from previous biopsy, affected relative, or willing to have biopsy at Columbus Children's Exclusion Criteria: - diagnosis of a neuromuscular disorder other than LGMD - unable to provide muscle tissue from previous or current biopsy - incapable of giving consent and not having a legal guardian willing or able to do so |
| Country | Name | City | State |
|---|---|---|---|
| United States | Nationwide Children's Hospital | Columbus | Ohio |
| Lead Sponsor | Collaborator |
|---|---|
| Nationwide Children's Hospital | Muscular Dystrophy Association, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
United States,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01403402 -
Congenital Muscle Disease Study of Patient and Family Reported Medical Information
|
||
| Terminated |
NCT03783923 -
A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
|
Phase 3 | |
| Completed |
NCT02635321 -
MRI and Muscle Involvement in Patients With Mutations in GMPPB
|
N/A | |
| Completed |
NCT00873782 -
Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy
|
Phase 1 | |
| Not yet recruiting |
NCT06399770 -
The Role of Muscle Ultrasound in Assessment of Sample of Patients With Limb-girdle Muscular Dystrophy
|
||
| Completed |
NCT04054375 -
Weekly Steroids in Muscular Dystrophy
|
Phase 2 | |
| Recruiting |
NCT00390104 -
Molecular Analysis of Patients With Neuromuscular Disease
|
||
| Recruiting |
NCT06246513 -
A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)
|
Phase 3 | |
| Completed |
NCT00104078 -
Study Evaluating MYO-029 in Adult Muscular Dystrophy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04475926 -
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
|
||
| Completed |
NCT02759302 -
MRI on Persons With Mutations in POMT2 Gene (LGMD2N)
|
N/A |